{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:04Z","timestamp":1791304324857,"version":"4.3.1"},"reference-count":16,"publisher":"Galenos Yayinevi","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2024,4,1]]},"DOI":"10.4274\/tjo.galenos.2024.04575","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T13:20:53Z","timestamp":1713532853000},"page":"112-115","source":"Crossref","is-referenced-by-count":3,"title":["Vitiligo in a Patient Receiving Adalimumab for Idiopathic Uveitis"],"prefix":"10.4274","volume":"54","author":[{"given":"Mehmet Fatih Ka\u011fan","family":"De\u011firmenci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatime Nil\u00fcfer","family":"Yal\u00e7\u0131nda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09273948.2019.1674890","article-title":"The Clinical Characteristics of Pediatric Non-Infectious Uveitis in Two Tertiary Referral Centers in Turkey","volume":"29","author":"Yal\u00e7\u0131nda\u011f","year":"2021","unstructured":"1. Yal\u00e7\u0131nda\u011f FN, G\u00fcng\u00f6r SG, De\u011firmenci MFK, Sar\u0131g\u00fcl Sezen\u00f6z A, \u00d6z\u00e7akar ZB, Bask\u0131n E, Yal\u00e7\u0131nkaya FF, Atilla H. The Clinical Characteristics of Pediatric Non-Infectious Uveitis in Two Tertiary Referral Centers in Turkey. Ocul Immunol Inflamm. 2021;29:282-289.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab","volume":"216","author":"Sim\u00f3n","year":"2008","unstructured":"2. Sim\u00f3n JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 2008;216:234-235.","journal-title":"Dermatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\uf061 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","unstructured":"3. Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC. Tumour necrosis factor-\uf061 inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015;173:641-650.","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Jung JM, Lee YJ, Won CH, Chang SE, Lee MW, Choi JH, Moon KC. Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response? Ann Dermatol. 2015;27:620-621.","DOI":"10.5021\/ad.2015.27.5.620"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58(2 Suppl):50-52.","DOI":"10.1016\/j.jaad.2006.05.035"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Posada C, Fl\u00f3rez A, Batalla A, Alc\u00e1zar JJ, Carpio D. Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence? Case Rep Dermatol. 2011;3:28-31.","DOI":"10.1159\/000324619"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/ecco-jcc\/jjv193","article-title":"Inflammatory Bowel Disease and the Risk of Autoimmune Diseases","volume":"10","author":"Wilson","year":"2016","unstructured":"7. Wilson JC, Furlano RI, Jick SS, Meier CR. Inflammatory Bowel Disease and the Risk of Autoimmune Diseases. J Crohns Colitis. 2016;10:186-193.","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-\uf061 in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","unstructured":"8. Kim NH, Torchia D, Rouhani P, Roberts B, Romanelli P. Tumor necrosis factor-\uf061 in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol. 2011;30:225-227.","journal-title":"Cutan Ocul Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","article-title":"Two case reports and literature review","volume":"39","author":"Massara","year":"2010","unstructured":"9. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \"class effect\" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313-319.","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\uf067 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","unstructured":"10. Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\uf067 for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132:1869-1876.","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223ra223.","DOI":"10.1126\/scitranslmed.3007811"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy","volume":"151","author":"BG","year":"2015","unstructured":"12. Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol. 2015;151:1110-1112.","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","unstructured":"13. Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 2016;74:370-371.","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study","volume":"138","author":"Bae","year":"2018","unstructured":"14. Bae JM, Kim M, Lee HH, Kim KJ, Shin H, Ju HJ, Kim GM, Park CJ, Park HJ. Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study. J Invest Dermatol. 2018;138:768-774.","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","unstructured":"15. M\u00e9ry-Bossard L, Bagny K, Chaby G, Khemis A, Maccari F, Marotte H, Perrot JL, Reguiai Z, Sigal ML, Avenel-Audran M, Boy\u00e9 T, Grasland A, Gillard J, Jullien D, Toussirot E. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31:181-186.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10792-015-0073-7","article-title":"Clinical and multimodal imaging characteristics of acute Vogt-Koyanagi-Harada disease unassociated with clinically evident exudative retinal detachment","volume":"36","author":"Attia","year":"2016","unstructured":"16. Attia S, Khochtali S, Kahloun R, Ammous D, Jelliti B, Ben Yahia S, Zaouali S, Khairallah M. Clinical and multimodal imaging characteristics of acute Vogt-Koyanagi-Harada disease unassociated with clinically evident exudative retinal detachment. Int Ophthalmol. 2016;36:37-44.","journal-title":"Int Ophthalmol"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:01:54Z","timestamp":1721998914000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2024.04575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2024.04575","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}